COMPARATIVE CLINICAL AND LABORATORY EVALUATION OF VARIOUS DRUGS FOR ETIOPATHOGENETIC THERAPY IN INFLUENZA AND ACUTE RESPIRATORY VIRAL INFECTIONS

The comparative clinical efficacy and safety of drugs "Citovir^®-3" powder for oral solution, "Citovir^®-3" syrup and "Immunal^®" oral solution in the treatment of influenza and ARVI in children were examined in the prospective clinical trial. Ninety children aged 2 to 6 years with influenza and acute respiratory viral infections of unknown etiology were included in the trial in accordance with inclusion criteria. All patients were randomized into 3 groups, each of which received one of the comparative drugs as a means of etiopathogenetic therapy. The investigational drugs were used in the age-specific dosage variances as outlined in patient information leaflet. The analysis of the obtained results showed that the efficacy of the investigational dosage forms of the "Citovir^®-3" (powder and syrup) against influenza and other ARVI exceeded the efficacy of the comparative drug "Immunal^®" in the speed of normalization of clinical and laboratory parameters. The "Citovir^®-3" (powder and syrup) contributes to statistically significant and clinically meaningful reduction in the duration of the febrile period and some catarrhal symptoms in comparison with "Immunal^®" in influenza and ARVI. "Citovir^®-3" (powder and syrup) facilitates the raise of secretory IgA production in the nasopharynx. All the investigational drugs were characterized as well tolerated. No adverse events or adverse drug reactions were found during the trial. Given the clinical and laboratory efficacy and safety profile of "Citovir^®-3" (powder and syrup) they can be recommended for their inclusion in the treatment of children with influenza and ARVI.

грипп, ОРВИ, этиопатогенетическая терапия, influenza, ARVI, etiopathogenetic therapy